Demographic profile, spectrum, awareness, and cost of renal replacement therapy of chronic kidney disease patients in a public tertiary care center in Rajasthan, India

R. Jhorawat, Ravi Kumar Meena, Seetaram Singh Kularaj, S. Sharma, P. Beniwal, Rakesh Gupta, D. Agarwal, V. Malhotra
{"title":"Demographic profile, spectrum, awareness, and cost of renal replacement therapy of chronic kidney disease patients in a public tertiary care center in Rajasthan, India","authors":"R. Jhorawat, Ravi Kumar Meena, Seetaram Singh Kularaj, S. Sharma, P. Beniwal, Rakesh Gupta, D. Agarwal, V. Malhotra","doi":"10.25259/ijms_240_2023","DOIUrl":null,"url":null,"abstract":"\n\nChronic kidney disease (CKD) is widely recognized as the leading cause of death worldwide. Diabetes and hypertension are common risk factors. This is the only study on CKD from Rajasthan that highlights basic CKD profiles in patients attending public tertiary care centers.\n\n\n\nThis observation study included diagnosed cases of CKD attending nephrology outpatient department (OPD) from January to December 2020. Data regarding the cause of CKD, its stage, mode of renal replacement therapy (RRT), and direct cost of medication were collected. The state runs various schemes, including free dialysis facilities for all, below-poverty level cards (below poverty line [BPL] cards, which had complete free treatment), and state health cards Bhamasha Swasthya Bima Yojana (BSSY) under the government scheme.\n\n\n\nA total of 252 patients were included in the study. Patients on dialysis were highest, followed by stage V and stage IV CKD, representing 33.73%, 18.65%, and 17.86%, respectively. Hypertension was the predominant cause of CKD, representing 29.37% and CKD (u) prevalence in our study was 14.68%. The direct cost of treatment at CKD stages I, II, III, IV, and V were Rs. 520 ($6.93), Rs. 2435.71 ($32.48), Rs. 3400 ($45.33), Rs. 3405.57 ($45.41), and Rs. 4815.97 ($64.21) per month, respectively. The monthly medicine cost of treatment on hemodialysis was Rs. 6730.60 ($89.74), Rs. 30,278 ($403.71) on peritoneal dialysis, and Rs. 5021.74 ($66.96) on renal transplant. BPL card holders were 8.33%, 39.68% had BSSY card, 16.27% had Insurance, and around one-third (35.71%) were without support.\n\n\n\nAge, socioeconomic status, and geographical location affect CKD etiology. The accessible dialysis facility, insurance, and government policies affect the selection of the RRT.\n","PeriodicalId":505755,"journal":{"name":"Indian Journal of Medical Sciences","volume":"34 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/ijms_240_2023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic kidney disease (CKD) is widely recognized as the leading cause of death worldwide. Diabetes and hypertension are common risk factors. This is the only study on CKD from Rajasthan that highlights basic CKD profiles in patients attending public tertiary care centers. This observation study included diagnosed cases of CKD attending nephrology outpatient department (OPD) from January to December 2020. Data regarding the cause of CKD, its stage, mode of renal replacement therapy (RRT), and direct cost of medication were collected. The state runs various schemes, including free dialysis facilities for all, below-poverty level cards (below poverty line [BPL] cards, which had complete free treatment), and state health cards Bhamasha Swasthya Bima Yojana (BSSY) under the government scheme. A total of 252 patients were included in the study. Patients on dialysis were highest, followed by stage V and stage IV CKD, representing 33.73%, 18.65%, and 17.86%, respectively. Hypertension was the predominant cause of CKD, representing 29.37% and CKD (u) prevalence in our study was 14.68%. The direct cost of treatment at CKD stages I, II, III, IV, and V were Rs. 520 ($6.93), Rs. 2435.71 ($32.48), Rs. 3400 ($45.33), Rs. 3405.57 ($45.41), and Rs. 4815.97 ($64.21) per month, respectively. The monthly medicine cost of treatment on hemodialysis was Rs. 6730.60 ($89.74), Rs. 30,278 ($403.71) on peritoneal dialysis, and Rs. 5021.74 ($66.96) on renal transplant. BPL card holders were 8.33%, 39.68% had BSSY card, 16.27% had Insurance, and around one-third (35.71%) were without support. Age, socioeconomic status, and geographical location affect CKD etiology. The accessible dialysis facility, insurance, and government policies affect the selection of the RRT.
印度拉贾斯坦邦一家公立三级医疗中心慢性肾病患者的人口概况、病谱、对肾脏替代疗法的认识和费用
慢性肾脏病(CKD)被公认为全球死亡的主要原因。糖尿病和高血压是常见的风险因素。这是拉贾斯坦邦唯一一项关于慢性肾脏病的研究,该研究强调了在公立三级医疗中心就诊的慢性肾脏病患者的基本情况。这项观察研究包括 2020 年 1 月至 12 月期间在肾内科门诊部(OPD)就诊的慢性肾脏病确诊病例。研究收集了有关慢性肾功能衰竭的病因、阶段、肾脏替代疗法(RRT)模式和直接药物费用的数据。该州实施了各种计划,包括政府计划下的全民免费透析设施、贫困线以下卡(贫困线以下卡,可享受完全免费治疗)和州健康卡 Bhamasha Swasthya Bima Yojana (BSSY)。透析患者最多,其次是五期和四期慢性肾脏病患者,分别占 33.73%、18.65% 和 17.86%。高血压是导致慢性肾脏病的主要原因,占 29.37%,在我们的研究中,慢性肾脏病(u)的发病率为 14.68%。CKD I、II、III、IV 和 V 期的直接治疗费用分别为每月 520 卢比(6.93 美元)、2435.71 卢比(32.48 美元)、3400 卢比(45.33 美元)、3405.57 卢比(45.41 美元)和 4815.97 卢比(64.21 美元)。血液透析的每月药费为 6730.60 卢比(89.74 美元),腹膜透析为 30278 卢比(403.71 美元),肾移植为 5021.74 卢比(66.96 美元)。持有 BPL 卡的人占 8.33%,持有 BSSY 卡的人占 39.68%,有保险的人占 16.27%,约三分之一(35.71%)的人没有支持。年龄、社会经济地位和地理位置影响着 CKD 病因,透析设施、保险和政府政策影响着 RRT 的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信